Eric Burak
Chief Tech/Sci/R&D Officer chez FUSN PHAR
Fortune : 820 607 $ au 31/03/2024
Profil
Eric Burak is currently the Chief Technology Officer at Fusion Pharmaceuticals, Inc. He previously held positions as the Director-Drug Metabolism & Pharmacokinetics at Guilford Pharmaceuticals, Inc., Vice President-Advanced Preclinical Development at Melinta Subsidiary Corp., Vice President-Development at Theracos, Inc., and Chief Scientific Officer at Centre For Probe Development & Commercialization.
Dr. Burak obtained his undergraduate degree from Drexel University and his doctorate degree from Temple University (Pennsylvania).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/01/2024 | 38 490 ( 0,05% ) | 820 607 $ | 31/03/2024 |
Postes actifs de Eric Burak
| Sociétés | Poste | Début |
|---|---|---|
| FUSN PHAR | Chief Tech/Sci/R&D Officer | 01/02/2017 |
Anciens postes connus de Eric Burak
| Sociétés | Poste | Fin |
|---|---|---|
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Chief Tech/Sci/R&D Officer | 01/02/2017 |
Theracos, Inc.
 Theracos, Inc. Pharmaceuticals: MajorHealth Technology Theracos, Inc. operates as a pharmaceutical research and development company. The firm supports preclinical & clinical research & development in inflammatory, metabolic and affective disorders. It specializes in all aspects of pharmaceutical development including medicinal and process chemistry, pharmacology, toxicology, pharmacokinetics, manufacturing, formulation, QA/QC, regulatory affairs and the design and execution of clinical trials. The company was founded by Edward P. Amento and is headquartered in Marlborough, MA. | Corporate Officer/Principal | 01/10/2012 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | - |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Corporate Officer/Principal | - |
Formation de Eric Burak
| Drexel University | Undergraduate Degree |
| Temple University (Pennsylvania) | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Theracos, Inc.
Theracos, Inc. Pharmaceuticals: MajorHealth Technology Theracos, Inc. operates as a pharmaceutical research and development company. The firm supports preclinical & clinical research & development in inflammatory, metabolic and affective disorders. It specializes in all aspects of pharmaceutical development including medicinal and process chemistry, pharmacology, toxicology, pharmacokinetics, manufacturing, formulation, QA/QC, regulatory affairs and the design and execution of clinical trials. The company was founded by Edward P. Amento and is headquartered in Marlborough, MA. | Health Technology |
| Fusion Pharmaceuticals, Inc. | |
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Health Technology |
